Exclusive Summary

• Capitalizing on the global patent cliff of a $12 billion former blockbuster, offering massive substitution and distribution opportunities in Rest of World (RoW) markets.
• Over 160,000 new Multiple Myeloma (MM) cases globally per year; as a WHO Essential Medicine and strict backbone therapy requiring long-term maintenance, it guarantees enormous rigid demand.
• Available in 5mg, 10mg, and 25mg full-range dosages, perfectly meeting clinical needs for dose titration and renal impairment adjustments.
• Supported by high-quality manufacturing and complete eCTD dossiers from China, enabling overseas distributors to achieve rapid local registration and market launch.
• Exceptional 'API+FDF' integrated cost advantage drastically lowers the prohibitive therapy cost of the originator, serving as a powerful weapon for winning local government tenders and penetrating out-of-pocket markets.